Management of Brain Tumors
The diagnostic and therapeutic approach for a patient with a brain tumor must begin with immediate MRI with gadolinium contrast to establish diagnosis and extent of disease, followed by maximal safe surgical resection to obtain tissue for histopathological and molecular characterization, which then guides subsequent treatment with radiotherapy and/or chemotherapy based on tumor type.
Initial Diagnostic Workup
Imaging
- MRI with gadolinium enhancement is the gold standard for brain tumor diagnosis 1, 2
- Perform within 24-48 hours post-surgery to assess extent of resection 1, 2
- CT scanning is inferior and should only be used when MRI is contraindicated
- Lumbar puncture is generally not indicated except for medulloblastoma staging 2
Tissue Diagnosis
Histological diagnosis is mandatory and must include sufficient tissue for molecular characterization 1. Key molecular markers to obtain:
- MGMT promoter methylation status - predicts temozolomide benefit 1, 2
- IDH mutations - major prognostic marker 1, 3
- 1p/19q co-deletion - identifies oligodendrogliomas with better prognosis 1
- EGFR status, BRAF mutations (in selected cases) 1
Initial Medical Stabilization
Cerebral Edema Management
- Start dexamethasone 4-8 mg/day for symptomatic patients with edema 4
- For acute neurologic deterioration, doses up to 16 mg/day in divided doses may be used 4
- Taper steroids as quickly as clinically possible to avoid toxicity (personality changes, immunosuppression, metabolic derangements, poor wound healing) 4
- Patients without significant mass effect or edema may not require steroids 4
Seizure Management
- Anticonvulsants should ONLY be given to patients who have had a seizure - prophylactic use is not recommended 4
- Use non-enzyme-inducing agents (levetiracetam, lamotrigine, pregabalin) to avoid drug interactions with chemotherapy 4, 5
- If started perioperatively, strongly consider discontinuation after the perioperative period in seizure-free patients 4
Treatment Algorithm by Tumor Type
Primary Malignant Gliomas (Glioblastoma, Anaplastic Astrocytoma)
Glioblastoma (WHO Grade IV)
Surgery: Maximal safe resection is the first therapeutic intervention 1, 2
- Extent of resection has prognostic value
- Use neuronavigation, intraoperative imaging, and functional mapping when appropriate
Standard Adjuvant Therapy:
Age-Based Modifications:
Anaplastic Gliomas (Grade III)
- Surgery followed by radiotherapy (60 Gy) is standard 1, 5
- Anaplastic oligodendroglioma with 1p/19q co-deletion: Add adjuvant chemotherapy 1
- Anaplastic astrocytoma: No proven benefit from adjuvant PCV chemotherapy 1
- Alternative approach: Chemotherapy alone initially with radiotherapy reserved for progression 1
Brain Metastases
Single or Oligometastatic Disease (1-3 lesions)
For symptomatic lesions causing mass effect with controlled systemic disease:
Stereotactic radiosurgery (SRS):
Multiple Metastases (>4 lesions)
- WBRT is standard for diffuse disease 4
- Consider systemic therapy based on primary tumor type
- Surgery reserved for symptomatic lesions causing mass effect 6
Follow-Up Protocol
Surveillance Imaging
- MRI every 3-4 months is standard practice 1
- Obtain baseline MRI 3-4 weeks after completing radiotherapy 3
- More frequent monitoring if clinically indicated
Clinical Monitoring
- Neurological function assessment
- Seizure control
- Steroid tapering - patients should be off steroids as early as possible 1
- Monitor for venous thrombotic events (common in residual/recurrent tumors) 1
Laboratory Monitoring
- Not routinely indicated unless:
Critical Pitfalls to Avoid
- Do not use prophylactic anticonvulsants - they don't prevent first seizures and cause drug interactions 4
- Do not continue steroids longer than necessary - toxicity accumulates after 3 weeks 4
- Do not delay molecular testing - MGMT and IDH status fundamentally alter treatment decisions 1
- Do not use CT when MRI is available - CT misses multiple lesions in metastatic disease 4
- Do not add WBRT to SRS reflexively - it worsens cognition without survival benefit 6
Recurrent Disease
- Repeat surgery with chemotherapy-impregnated wafers may prolong survival in selected patients 2
- Anaplastic astrocytomas respond better to chemotherapy than glioblastoma at recurrence 2
- For oligodendrogliomas with 1p/19q deletion, chemotherapy should be strongly considered 2
- Best managed within clinical trial protocols when available